FY26 Update

Open PDF
Stock Compumedics Ltd (CMP.ASX)
Release Time 6 Jul 2026, 10:43 a.m.
Price Sensitive Yes
 Compumedics Ltd FY26 Update
Key Points
  • Record FY26 shipped and invoiced revenue of $60.3M, up 18% year-on-year
  • Somfit and Nexus 360 SaaS recurring revenue up 70% YoY
  • FY26 EBITDA expected to grow, supported by revenue and cost discipline
Full Summary

Compumedics Ltd reported a record FY26 shipped and invoiced revenue of approximately $60.3 million, up 18% year-on-year. The company also reported FY26 sales orders of approximately $62.7 million, reflecting continued demand across its sleep, neurology, MEG, and connected platform businesses. Somfit and Nexus 360 SaaS recurring revenues increased approximately 70% on FY25. FY26 EBITDA is anticipated to grow, supported by revenue growth, cost discipline, and increasing contribution from higher quality recurring revenue platforms. The company expects to deliver further double-digit revenue growth in FY27, with EBITDA growth at a faster rate than revenue.

Guidance

FY26 shipped and invoiced revenue approximately $60.3M, FY26 EBITDA growth expected

Outlook

Compumedics targets double-digit revenue growth in FY27, driven by order book conversion, MEG activity, and the planned release of Somfit D in the USA.